Prescreening for clots also effective
Should lead to better treatment
High-risk and real-world patients responded
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study explores atezolizumab for myelodysplastic syndrome
FDA approval may come in 2019
Lower toxicity than conventional chemo
Please join our staff as we participate or present in the following presentations at the 2018 ASH Annual Meeting